본문으로 바로가기 주메뉴 바로가기

사용자별 맞춤메뉴

자주찾는 메뉴

추가하기
닫기

연구성과

contents area

detail content area

Comparison of prescription rates and clinical outcomes in acute coronary syndrome patients who...
  • 작성일2020-02-04
  • 최종수정일2020-02-10
  • 담당부서연구기획과
  • 연락처043-719-8033
  • 1,020

International Journal of Cardiology, 2019. 274, 21-26, DOI: https://doi.org/10.1016/j.ijcard.2018.09.011


Comparison of preion rates and clinical outcomes in acute coronary syndrome patients who underwent percutaneous coronary intervention using different P2Y12 inhibitors in a large observational study

Jeong Cheon Choe, Kwang Soo Cha;Jinhee Ahn;Jin Sup Park;HyeWon Lee;Jun-Hyok Oh;Jung Hyun Choi;Han Cheol Lee;Taek Jong Hong;Myung Ho Jeong;the Korea Acute Myocardial Infarction Registry–National Institutes of Health Investigators


Highlights

• Ticagrelor and prasugrel were used less often than clopidogrel.
• Both drugs were associated with better major adverse cardiac events and increased risk of in-hospital bleeding.
• Ticagrelor and prasugrel were not significantly different in in-hospital bleeding and MACEs.


Abstract

Background
To compare the preion rates, safety, and efficacy of contemporary P2Y12 inhibitors in acute coronary syndrome (ACS) patients following percutaneous coronary intervention (PCI).
Methods
From 9684 ACS patients who underwent PCI in a nationwide, real-world registry, we compared preion rates, bleeding, and major adverse cardiac events (MACEs: cardiac death, nonfatal myocardial infarction, or stroke) according to ticagrelor, prasugrel, or clopidogrel use.
Results
The preion rates of ticagrelor, prasugrel, and clopidogrel were 15.2%, 11.7%, and 73.0%, respectively. In-hospital bleeding occurred in 565 (5.8%) patients, with 108 (7.3%), 80 (7.9%), and 377 (5.3%) patients using ticagrelor, prasugrel, and clopidogrel, respectively, with significantly higher incidence in ticagrelor (p = 0.008) and prasugrel (p = 0.026) users than in clopidogrel users. Ticagrelor and prasugrel were not different in terms of in-hospital bleeding (p = 0.159). MACEs occurred in 804 patients (8.3%), with 82 (5.6%), 69 (6.1%), and 653 (9.2%) patients in ticagrelor, prasugrel, and clopidogrel, respectively (median follow-up, 468 days). Ticagrelor (p = 0.001) and prasugrel (p = 0.001) were associated with fewer MACEs than clopidogrel; the difference between ticagrelor and prasugrel for fewer MACEs was nonsignificant (p = 0.235).
Conclusions
In real-world ACS patients following PCI, ticagrelor and prasugrel were not prescribed at higher rates than clopidogrel, but were found to improve clinical outcomes, albeit they induced bleeding more frequently. No differences were observed in bleeding and outcomes in ticagrelor versus prasugrel.



  • 본 연구는 질병관리본부 연구개발과제연구비를 지원받아 수행되었습니다.
  • This research was supported by a fund by Research of Korea Centers for Disease Control and Prevention.


본 공공저작물은 공공누리  출처표시 조건에 따라 이용할 수 있습니다 본 공공저작물은 공공누리 "출처표시" 조건에 따라 이용할 수 있습니다.
TOP